Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Johnson and Johnson
Merck
Baxter
Harvard Business School

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Trimetrexate glucuronate - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic sources for trimetrexate glucuronate and what is the scope of freedom to operate?

Trimetrexate glucuronate is the generic ingredient in one branded drug marketed by Medimmune Oncology and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for trimetrexate glucuronate.

Summary for trimetrexate glucuronate
Recent Clinical Trials for trimetrexate glucuronate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Memorial Sloan Kettering Cancer CenterPhase 1
National Cancer Institute (NCI)Phase 1
Grupo Oncologico Cooperativo del SurPhase 2

See all trimetrexate glucuronate clinical trials

Medical Subject Heading (MeSH) Categories for trimetrexate glucuronate
Synonyms for trimetrexate glucuronate
2, 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-,mono-D-glucuronate
2,4-Diamino-5-methyl-6-((3,4,5-trimethoxyanilino)methyl)quinazoline mono-D-glucuronate
2,4-Quinazolinediamine, 5-methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)-, mono-D-glucuronate
5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine; (2S,3S,4S,5R)-2,3,4,5-tetrahydroxy-6-oxo-hexanoic acid
5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine; (2S,3S,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid
5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine; 2,3,4,5-tetrahydroxy-6-oxohexanoic acid
5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediaminetrihydrochloride
5-Methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]quinazoline-2,4-diamine D-glucuronate
6-(((3,4,5-Trimethoxyphenyl)amino)methyl)-5-methyl-2,4-quinazolinediamine glucuronate
AC1L1I26
AC1L7KE0
AN-36082
C19H23N5O3.C6H10O7
CHEMBL2007423
D-Glucuronic acid, compd. with 5-methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)-2,4-quinazolinediamine (1:1)
D-Glucuronic acid,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine (1:1)
D06239
DRG-0183
DTXSID90273968
L137U4A79K
LS-71744
NCI60_003150
Neuro_000185
Neutrexin (TN)
NSC 352122
NSC-352122
SCHEMBL3635
Trimetrexate D-glucuronate
Trimetrexate glucuronate (USAN)
Trimetrexate glucuronate [USAN]
trimetrexate glucuronic acid combination
Trimetrexate glucuronic acid salt
UNII-L137U4A79K

US Patents and Regulatory Information for trimetrexate glucuronate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-002 Jul 31, 1998 DISCN No No   Start Trial   Start Trial   Start Trial
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for trimetrexate glucuronate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993   Start Trial   Start Trial
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-002 Jul 31, 1998   Start Trial   Start Trial
Medimmune Oncology NEUTREXIN trimetrexate glucuronate INJECTABLE;INJECTION 020326-001 Dec 17, 1993   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Express Scripts
Medtronic
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.